VanEck Vectors Biotech ETF (BBH)
180.00
+1.00 (+0.56%)
USD |
Mar 01, 11:52
Price Chart
Key Stats
Customize
Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
---|---|---|---|
0.35% | 0.13% | 495.47M | 14836.63 |
Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
0.34% | 40.00% | 32.66M | Upgrade |
Basic Info
Investment Strategy | |
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Large Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Prospectus Objective | Specialty - Unaligned |
Fund Owner Firm Name | VanEck |
Prospectus Benchmark Index | |
MVIS US Listed Biotech 25 NR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Hao-Hung (Peter) Liao | 9.13 yrs |
Guo Hua (Jason) Jin | 3.00 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
30
32.66M
-4.597B
Category Low
7.682B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of January 31, 2021
Performance Versus Category
As of February 26, 2021. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of February 26, 2021.
Asset Allocation
Top 10 Holdings
Name | % Weight | Price | % Change |
---|---|---|---|
Amgen Inc | 11.95% | 227.31 | 1.06% |
Illumina Inc | 6.26% | 449.00 | 2.18% |
Gilead Sciences Inc | 6.11% | 62.25 | 1.38% |
Alexion Pharmaceuticals Inc | 5.42% | 153.49 | 0.48% |
Biogen Inc | 5.30% | 274.39 | 0.55% |
IQVIA Holdings Inc | 5.30% | 193.93 | 0.59% |
Novavax Inc | 5.12% | 234.98 | 1.62% |
Moderna Inc | 4.78% | 147.86 | -4.49% |
Guardant Health Inc | 4.57% | 150.70 | 2.39% |
Vertex Pharmaceuticals Inc | 4.44% | 211.96 | -0.28% |
News
Headline
Wire
Time (ET)
Business Wire
11/22 17:15
Business Wire
11/16 17:52
Basic Info
Investment Strategy | |
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified. |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Large Cap/Blend |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Prospectus Objective | Specialty - Unaligned |
Fund Owner Firm Name | VanEck |
Prospectus Benchmark Index | |
MVIS US Listed Biotech 25 NR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Hao-Hung (Peter) Liao | 9.13 yrs |
Guo Hua (Jason) Jin | 3.00 yrs |
Fundamentals
General | |
Distribution Yield | Upgrade |
Dividend Yield TTM (3-1-21) | 0.34% |
30-Day SEC Yield (2-24-21) | Upgrade |
7-Day SEC Yield | -- |
Number of Holdings | Upgrade |
Stock | |
Weighted Average PE Ratio | 26.66 |
Weighted Average Price to Sales Ratio | Upgrade |
Weighted Average Price to Book Ratio | Upgrade |
Weighted Median ROE | Upgrade |
Weighted Median ROA | Upgrade |
Forecasted Dividend Yield | Upgrade |
Forecasted PE Ratio | Upgrade |
Forecasted Price to Sales Ratio | Upgrade |
Forecasted Price to Book Ratio | Upgrade |
As of February 25, 2021
Growth Estimates
Fund Details
Key Dates | |
Inception Date | 12/20/2011 |
Last Annual Report Date | 9/30/2020 |
Last Prospectus Date | 2/1/2021 |
Attributes | |
Enhanced Index Fund | No |
Index Fund |
|
Inverse Fund | No |
Leveraged Fund | No |
Fund of Funds | No |
Currency Hedged Fund | No |
Synthetic Replication Fund | No |
Has Dividend Investment Plan | No |
Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
Business Wire
11/22 17:15
Business Wire
11/16 17:52